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important for the process of regeneration than for protection of
the liver, since the hepatic bile salt concentrations in this
situation are too low to be toxic.
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Letters to the Editor
744Reply to: ‘‘Transient elevation of serum bile salts after
partial hepatectomy is due to metabolic overload
and not to cholestasis’’To the Editor:
We appreciate Dr. Jansen‘s comments on our recent paper. We
consider cholestasis as retention of bile not only within
hepatocytes but also in the systemic circulation, because clinical
cholestatic status after hepatectomy or liver transplantation is
deﬁned as high serum levels of bile acids and bilirubin [1,2].
Meanwhile, as Dr. Jansen pointed out, bile acids have been con-
sidered as a trigger of liver regeneration [3] and elevated serum
levels would be a sign of hepatic overload [4]. However, in our
paper we have provided evidence indicating that intracellular
bile acids are maintained at a low level when the remnant liver
volume is excessively small and hepatocytes are vigorously pro-
liferating. We would like to address the relation between trans-
porters/pumps in the regulation of intracellular bile salt
concentration and regeneration after 90% hepatectomy. On day
1, DNA replication and cell proliferation are active as shown by
microarray analysis. At that time, Ntcp mRNA and protein levels
are decreased, and Cyp7a1 mRNA is also down-regulated. Since
Ntcp is a major transporter for bile acid uptake from the sinusoid
[5] and Cyp7a1 is the rate-limiting enzyme of bile acid synthesis,
intracellular bile acid concentration seems to be low at this pro-
liferative phase. Zhang et al. reported that overexpression of an
exogenous Cyp7a1 gene impaired liver regeneration after 70%
hepatectomy, which is accompanied by increased hepatocyte
apoptosis and liver injury [6]. To the contrary, on day 3, Cyp7a1
mRNA is up-regulated. Since cholesterol synthesis is enhanced
at this time, possibly to build proliferating cell membranes,
Cyp7a1 is transiently induced in response to cholesterol synthe-
sis, consistent with the results of a previous study [7]. NtcpJournal of Hepatology 2mRNA and protein levels are still decreased, and its cytoplasmic
localization reveals loss of transport activity. In addition, Mrp4
mRNA and protein levels are increased and its localization main-
tained at the basolateral membrane. These ﬁndings indicate that
massive hepatectomy results not only in a decrease in liver mass
but also in alterations of the bile acid transport system. Thus, pro-
liferating hepatocytes seem to be free from the inﬂux of bile salts
but able to excrete them de novo produced intracellularly in
response to cholesterol synthesis. Another interesting ﬁnding is
possible degradation of Ntcp protein during liver regeneration,
contributing to the protection of proliferating hepatocytes at
the expense of the transporter. Our paper does not provide infor-
mation on which factors trigger liver regeneration but we can say
that decreased intracellular bile acids may allow hepatocytes to
proliferate rapidly in response to massive hepatectomy, as cells
escape toxic effects induced by the substances.
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1994;14:2809–2821.Coffee consumption and reduced
HIV-HCV co-infected patien
ribavirin treatment: Results f
To the Editor:
Constentin and colleagues [1] reported key results about the pro-
tective effect of elevated coffee consumption (three or more cups/
day) on histological activity in patients with chronic hepatitis C.
These ﬁndings bring additional evidence to the potential hepato-
protective properties of coffee in chronic liver diseases, as already
suggested in studies showing its beneﬁcial effects on liver cancer
[2].
More recently, Freedman and colleagues [3] showed associa-
tions between elevated coffee consumption (three or more
cups/day) and early, week-20 and sustained virological response
(SVR) during re-treatment with peginterferon alfa-2a (180 lg/
wk) and ribavirin (1000–1200 mg/day) in the HALT trial. The
study also highlighted that the proportion of individuals tolerat-
ing the full dose of treatment was signiﬁcantly higher in those
patients drinking more than three cups of coffee/day. In addition,
during treatment, coffee drinkers were signiﬁcantly less likely to
have a dose reduction due to either low neutrophils or platelets.
These results provide important insights into the double role
that coffee consumption may play in slowing HCV progression,
reducing medical side effects and improving response to HCV
treatment. However, whether and to what extent elevated coffee
consumption may also reduce the burden of patients’ ‘‘personal
experience’’ with HCV disease and/or HCV treatment, as
expressed by self-reported symptoms/side effects, has not yet
been documented.
Individuals receiving HCV treatment experience a considerable
range of symptoms/side effects [4], in particular fatigue, neurocog-
nitive symptoms, depression, and problemsof anger controlwhich
can seriously compromise their quality of life [5] and undermine
adherence and continuity of treatment [6]. On the other hand, sev-
eral performance beneﬁts are attributed to coffee consumption
including physical endurance, fatigue reduction, and improve-
ments in mental concentration and alertness [7].
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Medically reported side effects document major toxicity
events during HCV treatment, whereas self-reported discomfort-
ing symptoms are known to express perceived toxicity and dis-
ease burden on patients’ daily life more accurately.
To test whether elevated coffee consumption can indeed
relieve the discomfort caused by side effects, we used data from
the HEPAVIH ANRS CO13 cohort of HIV-HCV-infected patients
[8]. Selection criteria for this analysis targeted patients receiving
antiretroviral therapy (ART) who started peginterferon alfa-2a
and ribavirin during follow-up and who had both complete data
about coffee consumption before starting treatment and self-
reported discomforting side effects during treatment at 3 months
and before the end of treatment, collected through self-adminis-
tered questionnaires (N = 106, 138 visits). A ﬁve-category vari-
able measured coffee consumption on a ﬁve-point scale: ‘‘no
consumption’’, ‘‘occasional consumption’’, ‘‘one cup per day’’,
‘‘two cups per day’’, ‘‘three or more cups of coffee per day’’.
Self-reported symptoms [9] detailed 30 treatment-related symp-
toms (deﬁned here as ‘‘self-reported side effects’’) over the previ-
ous 4 weeks and the discomfort they caused. This scale has
already been shown to capture HCV-treatment toxicity in HIV-
HCV infected patients [4].
Among the 106 selected patients, median [IQR] age was 44
[41–46] years, men accounted for 71% and most of the partici-
pants (80%) were HIV-infected through injecting drug use (IDU).
At enrollment, 86% of the patients had undetectable plasma HIV
RNA, 52% presented with severe ﬁbrosis (F3–4) and 13% had a
CD4 count <200/mm3. The median [IQR] number of self-reported
side effects causing discomfort was 3 [0–8] and 31% did not
report any discomforting side effects. A mixed model conﬁrmed
that individuals drinking more than three cups a day did not sig-
niﬁcantly change their consumption over time. A logistic regres-
sion model based on Generalized Estimating Equations was used
to study the relationship between coffee consumption before
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